The FDA has granted Fast Track designation to ADI-001 for the treatment of refractory systemic lupus erythematosus with extrarenal involvement.
ADI-001 is an allogeneic gamma delta CAR T-cell therapy that targets the B-cell antigen CD20. The Food and Drug Administration (FDA) has granted Fast Track designation to ADI-001 for the treatment ...
The FDA has accepted an investigational new drug application for ALLO-329, an allogeneic chimeric antigen receptor T-cell ...
Fate Therapeutics uses iPSC and gene editing to offer scalable off-the-shelf therapies. Read more to see why I rate FATE ...
Breakthrough research and investor enthusiasm prompted Cullinan Therapeutics to redirect one of its cancer programs toward ...
GlobalData on MSN11d
Genentech eyes lupus market for Gazyva with positive Phase III data readoutGenentech has shared positive data from the Phase III REGENCY trial with regulators in the US and EU. Roche’s subsidiary ...
The FDA has granted Fast Track Designation to Adicet Bio’s ADI-001, an allogeneic gamma delta CAR T-cell therapy, for ...
Biogen has bagged $250 million to advance a key pipeline prospect. | Biogen has bagged $250 million to advance a key pipeline ...
CRISPR's upcoming trial data and increasing demand for Casgevy drive Evercore's bullish outlook and a higher price target ...
Cabaletta Bio (CABA) announced new and updated clinical data from the first 10 patients dosed with resecabtagene autoleucel, or rese-cel, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback